Skip to content

Sigilon Therapeutics, Inc.

Delisted

CIK 1821323fmd_15HWNDBHSJD2ZWEP8S3XGVS63JManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2020 to Jun 30, 2023, 14 periods

Latest annual · FY2022

Millions
Total revenues
13
Operating income
(44)
Net income
(44)
Free cash flow
(52)

Latest quarter · Q2 FY2023

Millions
Total revenues
6
Operating income
(7)
Net income
(8)
Free cash flow
(4)
Open Financials

Sigilon Therapeutics, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue$12.9 million$9.6 million+34.8%10-K 2023-03-14 · proof
Operating income-$43.7 million-$75.6 million10-K 2023-03-14 · proof
Net income-$43.6 million-$77.3 million10-Q 2023-05-09 · proof
Cash from operating activities-$51.5 million-$78.4 million10-K 2023-03-14 · proof
Free cash flow-$52 million-$80.2 million10-K 2023-03-14 · proof
Total assets$87.3 million$144.4 million-39.5%10-K 2023-03-14 · proof
Total liabilities$48.1 million$67.2 million-28.4%10-K 2023-03-14 · proof
Cash and cash equivalents$42.1 million$107.1 million-60.7%10-K 2023-03-14 · proof
Total debt$25.4 million$21.7 million+16.6%10-K 2023-03-14 · proof
What was Sigilon Therapeutics, Inc.'s revenue in fiscal 2022?
Sigilon Therapeutics, Inc. reported revenue of $12.9 million for fiscal 2022 (the year ended Dec 31, 2022), against $9.6 million the year before (+34.8%). Source: the 10-K filed with the SEC on Mar 14, 2023. SEC
What was Sigilon Therapeutics, Inc.'s operating income in fiscal 2022?
Sigilon Therapeutics, Inc. reported operating income of -$43.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$75.6 million the year before. Source: the 10-K filed with the SEC on Mar 14, 2023. SEC
What was Sigilon Therapeutics, Inc.'s net income in fiscal 2022?
Sigilon Therapeutics, Inc. reported net income of -$43.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$77.3 million the year before. Source: the 10-Q filed with the SEC on May 9, 2023 (restated). SEC
What was Sigilon Therapeutics, Inc.'s cash from operating activities in fiscal 2022?
Sigilon Therapeutics, Inc. reported cash from operating activities of -$51.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$78.4 million the year before. Source: the 10-K filed with the SEC on Mar 14, 2023. SEC
What was Sigilon Therapeutics, Inc.'s free cash flow in fiscal 2022?
Sigilon Therapeutics, Inc. reported free cash flow of -$52 million for fiscal 2022 (the year ended Dec 31, 2022), against -$80.2 million the year before. Source: the 10-K filed with the SEC on Mar 14, 2023. SEC
What are Sigilon Therapeutics, Inc.'s total assets?
As of Dec 31, 2022, Sigilon Therapeutics, Inc. reported total assets of $87.3 million, against $144.4 million a year earlier (-39.5%). Source: the 10-K filed with the SEC on Mar 14, 2023. SEC
What are Sigilon Therapeutics, Inc.'s total liabilities?
As of Dec 31, 2022, Sigilon Therapeutics, Inc. reported total liabilities of $48.1 million, against $67.2 million a year earlier (-28.4%). Source: the 10-K filed with the SEC on Mar 14, 2023. SEC
What are Sigilon Therapeutics, Inc.'s cash and cash equivalents?
As of Dec 31, 2022, Sigilon Therapeutics, Inc. reported cash and cash equivalents of $42.1 million, against $107.1 million a year earlier (-60.7%). Source: the 10-K filed with the SEC on Mar 14, 2023. SEC
What is Sigilon Therapeutics, Inc.'s total debt?
As of Dec 31, 2022, Sigilon Therapeutics, Inc. reported total debt of $25.4 million, against $21.7 million a year earlier (+16.6%). Source: the 10-K filed with the SEC on Mar 14, 2023. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1821323&period_type=annual&limit=5"

Information only, not investment advice.